Bispecifics in R/R MM: Key Takeaways
Panelists discuss how their key takeaways emphasize the importance of communication and collaboration between academic centers and community practices to ensure equitable access to bispecific therapies, highlighting that it’s an exciting time in myeloma treatment with patient-friendly options that can be administered closer to home, and concluding that virtually no patient should be denied exposure to bispecific therapy before discontinuing treatment, while anticipating that de-escalated Q4 weekly schedules and trispecific agents will transform current practice patterns in the coming years.
EP: 1.MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data
EP: 2.MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data (Part 2)
EP: 3.Data Review of Teclistamab and Elranatamab in R/R MM
EP: 4.Expert Opinion on Modern Availability of Several Agents
EP: 5.Future of R/R MM: Emerging Bispecifics and Trispecifics
EP: 6.Optimal Dosing of Talquetamab
EP: 7.Optimal Dosing of Talquetamab (Part 2)
EP: 8.Talquetamab: Real-World Outcomes With Outpatient Dosing
EP: 9.Teclistamab: OPTEC Trial Overview
EP: 10.MonumenTAL-1: Safety Outcomes
EP: 11.Optimal Sequencing Strategies With Bispecifics in R/R MM
EP: 12.Bispecifics in R/R MM: Unanswered Questions
EP: 13.Clinical Scenario 1 With Bispecifics in R/R MM
EP: 14.Clinical Scenario 2 With Bispecifics in R/R MM
EP: 15.Bispecifics in R/R MM: Key Takeaways
Bispecifics in Relapsed/Refractory Multiple Myeloma (R/R MM): Key Takeaways
The closing discussion emphasizes the critical need for improved communication and collaboration between academic centers and community practices to facilitate broader implementation of bispecific antibodies. The panelists stress that equitable access to these transformative therapies should not be limited by geography or practice setting, highlighting the responsibility of academic institutions to support community oncologists in safely delivering these treatments. This collaboration is essential for ensuring that all appropriate patients can benefit from bispecific therapy regardless of where they receive care.
The experts express enthusiasm about the current state of multiple myeloma treatment, noting that the field is experiencing unprecedented therapeutic advances with increasingly patient-friendly options. The evolution toward treatments that can be administered closer to patients’ homes represents a significant improvement in reducing both time-related and financial toxicity associated with frequent travel to specialized centers. The movement toward de-escalated dosing schedules, including every-4-week administration and the emergence of trispecific antibodies, promises to further improve convenience and accessibility.
A key philosophical point emphasized is that virtually no patient with multiple myeloma should be denied exposure to bispecific therapy before treatment cessation or hospice care. This reflects the broad applicability and manageable safety profile of these agents across diverse patient populations, including those with significant comorbidities who might not be candidates for more intensive therapies. The panelists acknowledge that current practices will likely evolve significantly as experience grows and new agents become available, but the fundamental goal remains consistent: bringing these life-extending therapies to all patients who could benefit, regardless of their clinical setting or geographic location.
